HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Nicergoline in the treatment of patients after a mild ischemic stroke].

Abstract
25 patients with neurological and neuropsychological deficits after a mild ischaemic stroke were treated with nicergoline (Adavin 60 mg/d) versus placebo in a double blind cross-over trial (3 and 3 months). The patients were examined repeatedly by a neurologist and a neuropsychologist using a battery of tests (PPL, AVLT, Benton and Bourdon tests, number-repetition test). On completion of the trial the improvement of neurological signs (mainly cerebellar deficits) and neuropsychological impairments (in particular of attention and manual manipulation difficulties) was found to be more marked after the period of nicergoline treatment than after placebo. No drug-dependent side effects--including the influence on blood pressure--were observed in the whole group treated.
AuthorsEwa Piłkowska, Teresa Jakubowska, Karyna Witkowska, Jerzy Kulczycki
JournalNeurologia i neurochirurgia polska (Neurol Neurochir Pol) 2002 Nov-Dec Vol. 36 Issue 6 Pg. 1075-85 ISSN: 0028-3843 [Print] Poland
Vernacular TitleNicergolina w leczeniu chorych po lekkim udarze niedokrwiennym mózgu.
PMID12715685 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Vasodilator Agents
  • Nicergoline
Topics
  • Adult
  • Aged
  • Brain Ischemia (diagnosis, drug therapy, etiology)
  • Cognition Disorders (diagnosis, etiology)
  • Electrocardiography
  • Female
  • Humans
  • Hypertension (complications)
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Nicergoline (administration & dosage, therapeutic use)
  • Severity of Illness Index
  • Time Factors
  • Vasodilator Agents (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: